Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors contain transmembrane helices connecting an extracellular ligand-binding domain to a cytosolic domain that acts as an enzyme or associates with one. The enzyme component can be a kinase, phosphatase, or guanylyl cyclase. This dual-domain architecture allows these receptors to bind signaling molecules externally and catalyze intracellular phosphorylation or other enzymatic reactions, making them effective drug targets for cell division, differentiation, and immune responses.

Receptor tyrosine kinases bind growth factors and undergo conformational changes leading to receptor dimerization. Once dimerized, one receptor phosphorylates tyrosine residues on the other. These phosphorylated tyrosines then bind and phosphorylate target proteins, relaying the signal downstream through a cascade of phosphorylation events that activate mitogen-activated protein kinases essential for gene transcription and cell proliferation.

Major enzyme-linked receptor types include receptor tyrosine kinases that phosphorylate tyrosines on signaling proteins; cytokine receptors that associate with Janus kinases to phosphorylate STATs; receptor serine/threonine kinases involved in angiogenesis and bone development; receptor tyrosine phosphatases that remove phosphates to regulate cell growth; and receptor guanylyl cyclases that convert GTP to cyclic GMP for cardiovascular signaling.

Drugs can target enzyme-linked receptors at two main sites: the extracellular ligand-binding domain or the enzymatic domain itself. Ligand-binding drugs like becaplermin bind the receptor's external domain to activate it. Kinase inhibitors like imatinib and erlotinib directly block the enzymatic domain, preventing phosphorylation of target proteins and halting cancer cell multiplication or other pathological signaling cascades.

Cytokine receptors associate with intracellular tyrosine kinases such as Janus kinase, which phosphorylate signal transducers and activators of transcription downstream. Phosphorylated STATs translocate to the nucleus to regulate gene transcription. Ligands like interferons and colony-stimulating factors activate these receptors, generating immune responses and stimulating cell growth and differentiation essential for immune cell production.

Receptor guanylyl cyclases convert GTP into cyclic GMP, a second messenger mediating signaling pathways. These receptors are activated by natriuretic peptides released by cardiac cells, such as atrial natriuretic peptide and B-type natriuretic peptide. This signaling lowers blood pressure, reduces cardiac hypertrophy, and initiates bone growth, making these receptors valuable targets for treating congestive heart failure and other cardiovascular diseases.

Clinical applications include becaplermin for healing diabetic foot ulcers, imatinib and erlotinib for cancer therapy, aldesleukin for melanoma and renal cell carcinoma, filgrastim for neutropenia, dibotermin alfa for acute tibia fractures, and nesiritide or sacubitril for congestive heart failure. These drugs exploit enzyme-linked receptor mechanisms to treat cancer, immune deficiencies, bone disorders, and cardiovascular diseases.